Financial Performance - The company reported a net loss of $88.8 million for the nine months ended September 30, 2023, compared to a net loss of $86.8 million for the same period in 2022, resulting in an accumulated deficit of $423.3 million[86]. - The company reported a net loss of $30.6 million for Q3 2023, compared to a net loss of $30.0 million in Q3 2022, an increase of 2.2%[100]. - Net cash used in operating activities for the nine months ended September 30, 2023, was $83.5 million, compared to $60.8 million for the same period in 2022, an increase of 37.4%[116]. - Total operating expenses for the nine months ended September 30, 2023, were $94.9 million, compared to $90.2 million in the same period of 2022, an increase of 5.5%[104]. Cash and Financing - As of September 30, 2023, the company had $230.5 million in cash, cash equivalents, and marketable securities[89]. - The company generated $111.2 million in net cash from financing activities during the nine months ended September 30, 2023, primarily from the sale of common stock and pre-funded warrants[121]. - The company plans to finance operations through equity sales, debt financing, or collaborations, as it requires substantial additional capital to support ongoing operations[88]. - The company expects to finance operations through equity offerings, debt financings, and collaborations, as it has not yet commercialized any products[115]. Research and Development - The company is focusing resources on its first-in-class SMARCA2 degrader compounds and a selective CDK9 inhibitor, with plans to demonstrate clinical proof-of-concept in 2024[76]. - A Phase 1 multi-dose escalation clinical trial of the SMARCA2 degrader, PRT3789, is ongoing, with initial data expected to be shared in mid-2024[80]. - The CDK9 candidate, PRT2527, has shown high levels of target inhibition and potential for better tolerability compared to existing CDK9 inhibitors, with proof-of-concept data expected in 2024[83]. - The company has received IND clearance for PRT3645, a brain-penetrant CDK4/6 inhibitor, and is currently conducting a Phase 1 trial[85]. - Research and development expenses increased from $22.9 million in Q3 2022 to $26.3 million in Q3 2023, a rise of 15%[99]. - For the nine months ended September 30, 2023, research and development expenses totaled $73.1 million, up from $67.0 million in the same period of 2022, reflecting an increase of 9%[105]. Administrative Expenses - General and administrative expenses decreased from $7.5 million in Q3 2022 to $7.1 million in Q3 2023, a decline of 5.3%[101]. - Other income, net rose significantly from $0.4 million in Q3 2022 to $2.8 million in Q3 2023, an increase of 600%[102]. Company Classification - The company qualifies as an "emerging growth company" and may rely on reduced reporting requirements until it reaches total annual gross revenues of at least $1.235 billion or a market value exceeding $700 million[127]. - The company is classified as a "smaller reporting company" with a market value of stock held by non-affiliates below $700 million and annual revenue under $100 million[129]. - If the company remains a smaller reporting company after ceasing to be an emerging growth company, it can continue to rely on certain disclosure exemptions[129]. - The company is not required to provide quantitative and qualitative disclosures about market risk due to its status as a smaller reporting company[130].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39527 PRELUDE THERAPEUTICS INCORPORATED (Exact Name of Registrant as Specified in its Charter) Delaware 81-1384762 (State or other ...

| --- | --- | --- | --- | --- | --- | |---------------------------------------------------------------------------------------------|-------|-------|-------|-------|-------| | | | | | | | | lude | | | | | | | ERAPEUTICS | | | | | | | Corporate Presentation May 2023 Patient focused. Science driven. Precision oncology. | | | | | | Forward Looking Statements This presentation contains "forward-looking" statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39527 PRELUDE THERAPEUTICS INCORPORATED (Exact Name of Registrant as Specified in its Charter) Delaware 81-1384762 (State or othe ...

This presentation contains "forward-looking" statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: our plans to develop and commercialize small molecule therapies, our expectations about timing and ability to commence, enroll or complete clinical studies, present data and clinical results or updates, and to obtain regulatory approvals for PRT1419, PRT2527, PRT3645, PRT3789, our oral SMARCA2 candidate and other ca ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39527 PRELUDE THERAPEUTICS INCORPORATED (Exact name of Registrant as specified in its Charter) (State or other jurisdiction of incorp ...

Market Opportunity: • 70,000 patients with SMARCA4 mutation in the US/EU5 SMARCA2 Degrader 29 Driving The Programs to Key Milestones and Value Creation PRT2527 CDK9 • Present solid tumor data in 1H • RP2D in hematological malignancies in 2H • Present initial clinical data for hematological malignancies in 2H PRT1419 MCL1 PRT3645 CDK4/6 • Present initial clinical data in 2H SMARCA2 PROGRAM 2023 MILESTONES • Present solid tumor data in 1H • RP2D in solid tumors in early-2023 • RP2D in hematological malignanci ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39527 PRELUDE THERAPEUTICS INCORPORATED (Exact Name of Registrant as Specified in its Charter) Delaware 81-1384762 (State or ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39527 PRELUDE THERAPEUTICS INCORPORATED (Exact Name of Registrant as Specified in its Charter) (State or other jurisdiction of inc ...

Financial Performance - The net loss for the three months ended March 31, 2022, was $29.5 million, compared to a net loss of $21.3 million for the same period in 2021, representing an increase of $8.2 million [84]. - Total operating expenses for the three months ended March 31, 2022, were $30.3 million, up from $22.0 million in 2021, reflecting an increase of $8.3 million [96]. - The company has an accumulated deficit of $248.6 million as of March 31, 2022 [84]. - Cash used in operating activities was $21.9 million for the three months ended March 31, 2022, compared to $16.1 million for the same period in 2021 [106]. - General and administrative expenses rose by $2.0 million to $7.5 million for the three months ended March 31, 2022, from $5.5 million in the same period of 2021 [99]. - Other income, net increased by $0.2 million to $0.8 million for the three months ended March 31, 2022, primarily due to research and development tax credits [100]. Research and Development - Research and development expenses increased to $22.8 million for the three months ended March 31, 2022, from $16.5 million in 2021, an increase of $6.4 million [96]. - Research and development expenses increased by $6.4 million to $22.8 million for the three months ended March 31, 2022, compared to $16.5 million for the same period in 2021 [97]. - Research and development expenses by program included $5.4 million for discovery programs and $11.2 million for internal costs for the three months ended March 31, 2022 [98]. - PRT811, a candidate in the PRMT5 program, is being developed for biomarker-selected patients, focusing on its superior safety profile and brain penetrant properties [78]. - PRT1419, designed as a potent inhibitor of MCL1, is currently enrolling patients in Phase 1 clinical trials for hematologic malignancies [80]. Cash and Funding - As of March 31, 2022, the company had $266.2 million in cash, cash equivalents, and marketable securities, expected to fund operations into the second half of 2024 [86]. - The company expects existing cash resources to fund operating expenses into the second half of 2024 [101]. - The company plans to finance operations through equity sales, debt financings, or collaborations, highlighting the need for substantial additional capital [85]. - Net cash provided by investing activities was $41.5 million for the three months ended March 31, 2022, primarily from maturities of marketable securities [109]. - Financing activities provided $0.2 million from the exercise of stock options during the three months ended March 31, 2022, compared to $161.8 million in the same period of 2021 [110]. Revenue Generation - The company has not recognized any revenue to date and does not expect to generate revenue from product sales in the foreseeable future [88]. - The company has not yet commercialized any product and does not expect to generate revenue from product sales for several years [101]. - The company has advanced four clinical candidates and plans to file two INDs in the second half of 2022 [76].